Augmentin and Norcuron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Augmentin (amoxicillin; clavulanate potassium) and Norcuron (vecuronium bromide). Common drug interactions include anaphylactic shock among females and blister among males.

The phase IV clinical study analyzes what interactions people have when they take Augmentin and Norcuron. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Augmentin?

Augmentin has active ingredients of amoxicillin; clavulanate potassium. It is often used in sinusitis. eHealthMe is studying from 42,620 Augmentin users. Check the latest studies of Augmentin.

What is Norcuron?

Norcuron has active ingredients of vecuronium bromide. eHealthMe is studying from 430 Norcuron users. Check the latest studies of Norcuron.



On Jul, 18, 2026

12 people who take Augmentin and Norcuron together, and have interactions are studied.

Augmentin and Norcuron drug interactions.

What are the common drug interactions of Augmentin and Norcuron, by gender? *:

female:

  1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  2. Extravasation (leakage of a fluid)
  3. Weight increased
  4. Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)
  5. Capillary leak syndrome (capillary leaks plasma)
  6. Crystalluria present
  7. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  8. Drug maladministration
  9. Erythema (redness of the skin)
  10. Hypotension (abnormally low blood pressure)

male:

  1. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  2. Cerebral oedema (swelling of brain)
  3. Pyrexia (fever)
  4. Red eye
  5. Skin disorder (skin disease)
  6. Urethritis non-specific (inflammation of the urethra- non-specific)
  7. Acute circulatory failure (shock)
  8. Alanine aminotransferase increased
  9. Aspartate aminotransferase increased
  10. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)

What are the common drug interactions of Augmentin and Norcuron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  2. Hypoxia (low oxygen in tissues)

20-29:

n/a

30-39:

  1. Crystalluria present
  2. Drug maladministration
  3. Urinary retention (the inability to completely or partially empty the bladder)

40-49:

  1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  2. Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)
  3. Erythema (redness of the skin)
  4. Hypotension (abnormally low blood pressure)
  5. Oxygen saturation decreased
  6. Ventricular extrasystoles (premature cardiac contraction)

50-59:

  1. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  2. Cerebral oedema (swelling of brain)
  3. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  4. Epidermal necrolysis (skin condition that is usually caused by a reaction to drugs)
  5. Pneumonia
  6. Stevens johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  7. Fall
  8. Hepatitis cholestatic (flow of bile from the liver is slowed or blocked)
  9. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  10. Pyrexia (fever)

60+:

  1. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  2. Extravasation (leakage of a fluid)
  3. Weight increased
  4. Arrhythmia (irregular heartbeat)
  5. Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)
  6. Capillary leak syndrome (capillary leaks plasma)
  7. Collapse (sudden functional breakdown)
  8. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  9. Skin disorder (skin disease)
  10. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

What are the existing conditions these people have? *

  1. Anaesthesia: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Augmentin and Norcuron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Augmentin and Norcuron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Augmentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Norcuron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Augmentin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Norcuron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on amoxicillin; clavulanate potassium and vecuronium bromide (the active ingredients of Augmentin and Norcuron, respectively), and Augmentin and Norcuron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: